42 patents
Page 2 of 3
Utility
Modulators of Methyl Modifying Enzymes, Compositions and Uses Thereof
29 Jul 21
Jehrod B. Brenneman, Alexandre Côté, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Ludivine Moine
Filed: 8 Nov 18
Utility
Modulators of Methyl Modifying Enzymes, Compositions and Uses Thereof
8 Jul 21
Alexandre Côté, Avinash Khanna, Ludivine Moine
Filed: 17 May 19
Utility
EZH2 Inhibitor-induced Gene Expression
3 Jun 21
Provided herein are methods of treating subjects characterized as having a gene signature that is indicative of EZH2-inhibitor response, methods for determining said gene signature, and methods of determining which subjects may be responsive to cancer treatments based on said gene signature.
William D. Bradley, Barbara M. Bryant, Patrick Trojer
Filed: 10 Jul 18
Utility
LSD1 inhibitors and medical uses thereof
25 May 21
Francois Brucelle, Victor S. Gehling, Avinash Khanna
Filed: 1 Nov 19
Utility
P300/CBP Hat Inhibitors
22 Apr 21
Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
Filed: 15 Feb 19
Utility
P300/CBP Hat Inhibitors
4 Mar 21
Jonathan E. Wilson, Julian R. Levell
Filed: 15 Feb 19
Utility
Methods of treating myeloproliferative disorders
16 Feb 21
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
Adrian Senderowicz, Michael Cooper
Filed: 7 Oct 20
Utility
Methods of Treating Myeloproliferative Disorders
4 Feb 21
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
Adrian Senderowicz, Michael Cooper
Filed: 7 Oct 20
Utility
Pharmacokinetic Enhancement of EZH2 Inhibitors Through Combination Therapies
6 Jan 21
Provided herein are pharmaceutical composition comprising an effective amount of (R)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, or a pharmaceutically acceptable salt thereof and an effective amount of cobicistat, or a pharmaceutically acceptable salt thereof.
Adrian Senderowicz
Filed: 26 Dec 18
Utility
Therapeutic Compounds and Uses Thereof
23 Dec 20
Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
Filed: 27 May 20
Utility
Modulators of Methyl Modifying Enzymes, Compositions and Uses Thereof
7 Oct 20
Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
Filed: 22 Apr 20
Utility
LSD1 Inhibitors and Medical Uses Thereof
30 Sep 20
Francois Brucelle, Victor S. Gehling, Avinash Khanna
Filed: 31 Oct 19
Utility
Therapeutic compounds and uses thereof
29 Jun 20
Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
Filed: 20 Nov 18
Utility
Modulators of methyl modifying enzymes, compositions and uses thereof
22 Jun 20
Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
Filed: 17 Apr 19
Utility
Combinations of EZH2 Inhibitors with Further Agents for Use In the Treatment of Cancer
25 Mar 20
Provided herein are methods of treating cancer using an effective amount of an EZH2 inhibitor and an effective amount of a second agent.
Shilpi Arora, Srividya Balasubramanian, William D Bradley, Patrick Trojer
Filed: 26 Jul 16
Utility
Markers for Personalized Cancer Treatment with LSD1 Inhibitors
4 Mar 20
Provided herein are methods of treating cancers characterized by a high expression of GFIIB, comprising administering a therapeutically effective amount of a KDMIA inhibitor.
John McGrath, Patrick Trojer
Filed: 7 Dec 17
Utility
Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
2 Mar 20
Brian K. Albrecht, Alisha Arrigo, Donald Corson, Victor S. Gehling, Bruno Patrice Haché, Jean-Christophe Harmange, Jonathan Lane
Filed: 24 Aug 16
Utility
LSD1 inhibitors and uses thereof
6 Jan 20
Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Rishi G. Vaswani
Filed: 21 Apr 16
Utility
LSD1 inhibitors and medical uses thereof
30 Dec 19
Francois Brucelle, Victor S. Gehling, Avinash Khanna
Filed: 25 Oct 17
Utility
Solid Dispersions of (R)-N-((4-METHOXY-6-METHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-2-METHYL-1-(1-(1-(2,2,2-TRIFLUOROETHYL)PIPERIDIN-4-YL)ETHYL)-1H-INDOLE-3-CARBOXAMIDE
18 Dec 19
Provided herein are solid dispersions of (R)—N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methy 1)-2-methyl-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H indole-3-carboxamide, pharmaceutically acceptable compositions comprising the dispersions, and methods of using said dispersions and compositions in the treatment of various conditions.
Alisha Arrigo, Donald Corson, Jean-Christophe Harmange
Filed: 17 Jan 18